Contrary to these studies, Nakahara et al. showed that among 20 EGFR/ALK-wild type NSCLC patients treated with anti-PD1 therapy, responders had a significant reduction in TCR diversity 6 weeks after treatment initiation compared to non-responders [133]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.